MIRA Pharmaceuticals, Inc. (MIRA) analyst actions
Rating and price-target actions on MIRA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MIRA overview →
3 measured MIRA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study | Press release | +0.82% | -2.46% | |
| MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | Press release | -1.34% | -5.66% | |
| MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain | Press release | +1.10% | +2.20% |
Keep exploring
More MIRA: earnings → · SEC filings → · MIRA overview →